PBLSParabilis Medicines, Inc.vs its industry peers
A metric-by-metric comparison of Parabilis Medicines, Inc. against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PBLSThis | $3.6B#8 | — | 3.4x#5 | — | — | — | — | 0.0%#3 | — | — | — | — |
| EWTX | $4.2B#1 | — | 9.3x#12 | — | — | -25.4%#10 | — | -0.0%#5 | -50.9%#8 | — | — | — |
| ARQT | $4.1B#2 | 146.6x#4 | 18.4x#14 | 10.8x#4 | 91.3%#4 | 88.5%#2 | -3.3%#4 | -7.3%#6 | -4.1%#4 | — | 30.3%#5 | — |
| TNGX | $4.0B#3 | — | 3.9x#7 | 64.5x#8 | 48.3%#5 | 22.0%#7 | -178.4%#7 | -9.9%#7 | — | — | — | — |
| LQDA | $3.8B#4 | 30.1x#3 | 19.3x#15 | 23.8x#6 | 1031.2%#2 | 47.1%#6 | -32.5%#5 | -35.3%#13 | — | — | — | — |
| ABCL | $3.8B#5 | — | 4.2x#8 | 50.0x#7 | 160.6%#3 | 10.1%#8 | -289.0%#8 | -16.3%#10 | -28.0%#5 | — | 128.6%#1 | — |
| XENE | $3.8B#6 | — | 3.0x#3 | 500.3x#9 | — | -47.6%#12 | -4974.3%#9 | -27.8%#11 | -32.5%#6 | — | -5.7%#8 | — |
| OGN | $3.6B#7 | 17.8x#2 | 3.0x#4 | 0.6x#2 | -2.9%#8 | -78.4%#13 | 14.9%#2 | 15.7%#2 | 4.9%#2 | 5#1 | 111.7%#4 | 2.4%#2 |
| ACAD | $3.6B#9 | 9.3x#1 | 2.7x#1 | 3.3x#3 | 11.9%#6 | 73.0%#3 | 9.8%#3 | 29.9%#1 | 11.4%#1 | — | -7.3%#9 | — |
| VKTX | $3.4B#10 | — | 5.8x#11 | — | — | -227.1%#15 | — | -61.1%#15 | — | — | -26.0%#11 | — |
| DYN | $3.4B#11 | — | 4.8x#9 | — | — | -40.6%#11 | — | -0.0%#4 | -1301.5%#9 | — | -25.0%#10 | — |
| ELVN | $3.3B#12 | — | 3.7x#6 | — | — | -16.5%#9 | — | -11.6%#9 | — | — | 126.2%#2 | — |
| AMLX | $3.3B#13 | — | 13.7x#13 | — | -100.0%#9 | 52.0%#5 | — | -60.5%#14 | — | — | 115.9%#3 | — |
| IRON | $3.1B#14 | — | 4.8x#10 | — | — | -94.0%#14 | — | -32.9%#12 | -39.0%#7 | — | -4.0%#7 | — |
| IDYA | $3.1B#15 | — | 2.8x#2 | 14.0x#5 | 3024.4%#1 | 58.6%#4 | -72.8%#6 | -10.4%#8 | — | — | 1.2%#6 | — |
| BHC | $3.0B#16 | — | — | 0.3x#1 | 6.7%#7 | 441.3%#1 | 17.7%#1 | — | 3.7%#3 | — | — | 11.8%#1 |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. This table timed out mid-build, so it covers part of the group; ranks are within the rows shown and it fills in shortly. Table built 2026-11-04.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice